17-DMAG
| Code | Size | Price |
|---|
| AG-CN2-0540-M001 | 1 mg | £40.00 |
Quantity:
| AG-CN2-0540-M005 | 5 mg | £100.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short Term: +4°C, Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
17-[2-(Dimethylamino)ethyl]amino-17-desmethoxy-geldanamycin; KOS-1022; Alvespimycin; NSC 707545
Appearance:
Purple to black powder.
CAS:
467214-20-6
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Protect from light when in solution.
Hazards:
H302, H312, H319
InChi:
InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1
InChiKey:
KUFRQPKVAWMTJO-LMZWQJSESA-N
Long Description:
Chemical. CAS: 467214-20-6. Formula: C32H48N4O8. MW: 616.8. Less toxic, more potent synthetic derivative of geldanamycin (Prod. No. BVT-0196 https://adipogen.com/bvt-0196-geldanamycin.html ). Angiogenesis inhibitor. Heat shock protein 90 (HSP90) inhibitor. Apoptosis inducer. Shows higher antitumor activity than 17-AAG (Prod. No. BVT-0244 https://adipogen.com/bvt-0244-17-aag.html ).
MDL:
MFCD04973892
Molecular Formula:
C32H48N4O8
Molecular Weight:
616.8
Package Type:
Plastic Vial
Precautions:
P270, P280, P301, P312, P302, P352, P312
Product Description:
Less toxic, more potent synthetic derivative of geldanamycin (Prod. No. BVT-0196 https://adipogen.com/bvt-0196-geldanamycin.html ). Angiogenesis inhibitor. Heat shock protein 90 (HSP90) inhibitor. Apoptosis inducer. Shows higher antitumor activity than 17-AAG (Prod. No. BVT-0244 https://adipogen.com/bvt-0244-17-aag.html ).
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
[H][C@@]1(C[C@@H](O)[C@H](O)[C@@H](C)O1)O[C@@H]1C[C@@](O)(O[C@H](C=CC)[C@H]1C)[C@@H](C)[C@H](O)[C@H](C)[C@@]1([H])OC(=O)C(OC)=CC(C)=C[C@@H](C)[C@@H](O)[C@H](CC)[C@H](O)[C@H](C)CC(C)=CC=C[C@@H]1OC
Solubility Chemicals:
Soluble in water, 100% ethanol (10mg/ml) or DMSO (25mg/ml).
Source / Host:
Semi-synthetic derivative from geldanamycin.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C.
References
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats: M.J. Egorin, et al.; Cancer Chemother. Pharmacol. 49, 7 (2002) | Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats: S.M. Musser, et al.; Cancer Chemother. Pharmacol. 52, 139 (2003) | Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90: J.M. Jez, et al.; Chem. Biol. 10, 361 (2003) | Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator: G. Kaur, et al.; Clin. Cancer Res. 10, 4813 (2004) | Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin: E.E. Bull, et al.; Clin. Cancer Res. 10, 8077 (2004) | Synthesis and biological activities of novel 17-aminogeldanamycin derivatives: Z.Q. Tian, et al.; Bioorg. Med. Chem. 12, 5317 (2004) | Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models: V. Smith, et al.; Cancer Chemother. Pharmacol. 56, 126 (2005) | In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative: M. Hollingshead, et al.; Cancer Chemother. Pharmacol. 56, 115 (2005) | Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance: E.R. Glaze, et al.; Cancer Chemother. Pharmacol. 56, 637 (2005) | Structure-based design of 7-carbamate analogs of geldanamycin: G. Rastelli, et al.; Biooorg. Med. Chem. Lett. 15, 5016 (2005) | Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry: K. Hwang, et al.; J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 35 (2006) | Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art: H. Mellatyar, et al.; Biomed. Pharmacother. 102, 608 (2018) (Review)